Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
Sign Up to like & getrecommendations! Published in 2020 at "Cephalalgia"
DOI: 10.1177/0333102420912726
Abstract: Background This study reports the long-term safety and efficacy of erenumab in chronic migraine patients. Methods This was a 52-week open-label extension study of a 12-week double-blind treatment phase study. During the double-blind treatment phase,… read more here.
Keywords: treatment; study; treatment phase; double blind ... See more keywords